These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 30416684)

  • 1. CXCR4- and BCR-triggered integrin activation in B-cell chronic lymphocytic leukemia cells depends on JAK2-activated Bruton's tyrosine kinase.
    Montresor A; Toffali L; Rigo A; Ferrarini I; Vinante F; Laudanna C
    Oncotarget; 2018 Oct; 9(80):35123-35140. PubMed ID: 30416684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK2 tyrosine kinase mediates integrin activation induced by CXCL12 in B-cell chronic lymphocytic leukemia.
    Montresor A; Toffali L; Mirenda M; Rigo A; Vinante F; Laudanna C
    Oncotarget; 2015 Oct; 6(33):34245-57. PubMed ID: 26413812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of Protein Tyrosine Phosphatase Receptor Type γ Suppresses Mechanisms of Adhesion and Survival in Chronic Lymphocytic Leukemia Cells.
    Montresor A; Toffali L; Fumagalli L; Constantin G; Rigo A; Ferrarini I; Vinante F; Laudanna C
    J Immunol; 2021 Jul; 207(2):671-684. PubMed ID: 34162728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Bruton's tyrosine kinase in B cells and malignancies.
    Pal Singh S; Dammeijer F; Hendriks RW
    Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noncatalytic Bruton's tyrosine kinase activates PLCγ
    Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
    J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
    Robak T; Robak P
    Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.
    Tissino E; Benedetti D; Herman SEM; Ten Hacken E; Ahn IE; Chaffee KG; Rossi FM; Dal Bo M; Bulian P; Bomben R; Bayer E; Härzschel A; Gutjahr JC; Postorino M; Santinelli E; Ayed A; Zaja F; Chiarenza A; Pozzato G; Chigaev A; Sklar LA; Burger JA; Ferrajoli A; Shanafelt TD; Wiestner A; Del Poeta G; Hartmann TN; Gattei V; Zucchetto A
    J Exp Med; 2018 Feb; 215(2):681-697. PubMed ID: 29301866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies.
    ten Hacken E; Burger JA
    Pharmacol Ther; 2014 Dec; 144(3):338-48. PubMed ID: 25050922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic Lymphocytic Leukemia: Disease Biology.
    Koehrer S; Burger JA
    Acta Haematol; 2024; 147(1):8-21. PubMed ID: 37717577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative analysis of normal versus CLL B-lymphocytes reveals patient-specific variability in signaling mechanisms controlling LFA-1 activation by chemokines.
    Montresor A; Bolomini-Vittori M; Simon SI; Rigo A; Vinante F; Laudanna C
    Cancer Res; 2009 Dec; 69(24):9281-90. PubMed ID: 19934331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).
    Woyach JA; Bojnik E; Ruppert AS; Stefanovski MR; Goettl VM; Smucker KA; Smith LL; Dubovsky JA; Towns WH; MacMurray J; Harrington BK; Davis ME; Gobessi S; Laurenti L; Chang BY; Buggy JJ; Efremov DG; Byrd JC; Johnson AJ
    Blood; 2014 Feb; 123(8):1207-13. PubMed ID: 24311722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia.
    Chen SS; Chang BY; Chang S; Tong T; Ham S; Sherry B; Burger JA; Rai KR; Chiorazzi N
    Leukemia; 2016 Apr; 30(4):833-43. PubMed ID: 26582643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia.
    Aslan B; Kismali G; Iles LR; Manyam GC; Ayres ML; Chen LS; Gagea M; Bertilaccio MTS; Wierda WG; Gandhi V
    Blood Cancer J; 2022 May; 12(5):80. PubMed ID: 35595730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of NF-κB in B cell receptor signaling through Bruton's tyrosine kinase-dependent phosphorylation of IκB-α.
    Pontoriero M; Fiume G; Vecchio E; de Laurentiis A; Albano F; Iaccino E; Mimmi S; Pisano A; Agosti V; Giovannone E; Altobelli A; Caiazza C; Mallardo M; Scala G; Quinto I
    J Mol Med (Berl); 2019 May; 97(5):675-690. PubMed ID: 30887112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The VLA-4 integrin is constitutively active in circulating chronic lymphocytic leukemia cells via BCR autonomous signaling: a novel anchor-independent mechanism exploiting soluble blood-borne ligands.
    Tissino E; Gaglio A; Nicolò A; Pozzo F; Bittolo T; Rossi FM; Bomben R; Nanni P; Cattarossi I; Zaina E; Zimbo AM; Ianna G; Capasso G; Forestieri G; Moia R; Datta M; Härzschel A; Olivieri J; D'Arena G; Laurenti L; Zaja F; Chiarenza A; Palumbo GA; Martino EA; Gentile M; Rossi D; Gaidano G; Del Poeta G; Laureana R; Del Principe MI; Maity PC; Jumaa H; Hartmann TN; Zucchetto A; Gattei V
    Leukemia; 2024 Oct; 38(10):2127-2140. PubMed ID: 39143370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrin Signaling Shaping BTK-Inhibitor Resistance.
    Polcik L; Dannewitz Prosseda S; Pozzo F; Zucchetto A; Gattei V; Hartmann TN
    Cells; 2022 Jul; 11(14):. PubMed ID: 35883678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional consequences of inhibition of Bruton's tyrosine kinase by ibrutinib in chronic lymphocytic leukemia.
    Chen SS; Chiorazzi N
    Hematol Oncol; 2023 Jun; 41 Suppl 1():119-128. PubMed ID: 37294973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bruton's tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia.
    Kil LP; de Bruijn MJ; van Hulst JA; Langerak AW; Yuvaraj S; Hendriks RW
    Am J Blood Res; 2013; 3(1):71-83. PubMed ID: 23359016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The B cell antigen receptor controls integrin activity through Btk and PLCgamma2.
    Spaargaren M; Beuling EA; Rurup ML; Meijer HP; Klok MD; Middendorp S; Hendriks RW; Pals ST
    J Exp Med; 2003 Nov; 198(10):1539-50. PubMed ID: 14610042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.
    de Rooij MF; Kuil A; Geest CR; Eldering E; Chang BY; Buggy JJ; Pals ST; Spaargaren M
    Blood; 2012 Mar; 119(11):2590-4. PubMed ID: 22279054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.